Global Biopharmaceutical Company - Bristol Myers Squibb
Areas of focus
Bristol Myers Squibb is committed to discovering, developing and delivering transformational medicines in areas where we believe we have an opportunity to make a meaningful difference for patients.
2022 First Quarter Results >
Bristol Myers Squibb reports first quarter revenues of $11.6 Billion; GAAP EPS of $0.59 and non-GAAP EPS of $1.96 which include net impact of ($0.10) per share due to acquired IPRD charges partially offset by licensing income. Read more, including important cautionary statements about forward-looking information.
Emmy winner Sterling K. Brown explores cancer survivorship during a global pandemic.
Moving forward.
Together.
We’re looking for people who want to change lives. Join us as we transform patients’ lives through science.
Learn more about how we strive to produce sustained strong performance and shareholder value.
Looking for Answers?
Quick links to helpful resources.